# Binghe Xu

Source: https://onco.cc/people/xu-binghe/  
OnCo record `xu-binghe` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval.

## Summary

Binghe Xu is Professor of Medical Oncology and Director of the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. He was principal investigator of OptiTROP-Breast01, the Chinese trial that secured approval for the TROP2 antibody-drug conjugate sacituzumab tirumotecan before any Western approval, and has led Chinese breast cancer trials of pyrotinib, dalpiciclib and other antibody-drug conjugates in pretreated triple-negative and HR-positive disease. His publications include the PHOEBE trial comparing pyrotinib plus capecitabine with lapatinib plus capecitabine in HER2-positive metastatic breast cancer. Several of his trials produced first approvals in China for drugs from Sichuan Kelun-Biotech and Jiangsu Hengrui Pharmaceuticals.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; Director, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences
- Specialisms: Breast cancer; Antibody-drug conjugates; TROP2; Clinical trials

## Sources

- Cancer Hospital, CAMS: https://www.cicams.ac.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20B%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20breast%20cancer

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [HER2](https://onco.cc/targets/her2/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/), [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- institutions: [Cancer Hospital, Chinese Academy of Medical Sciences](https://onco.cc/institutions/cams-cancer-hospital/)
- key papers: [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/), [TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer](https://onco.cc/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/)
- trials: [DAWNA-1](https://onco.cc/trials/dawna-1/)

---
JSON: https://onco.cc/api/v1/entities/xu-binghe.json